TEL AVIV, Israel--(BUSINESS WIRE)--Speaking before the 5th International Conference on Relaxin and Related Peptides in Maui, Hawaii, Dr. Ronen Shemesh of Compugen Ltd. (NASDAQ:CGEN) today presented experimental results for three Compugen discovered Relaxin related molecules that could have therapeutic activity in various clinical indications, including labor complications, infertility, inflammation, congestive heart failure and fibrotic diseases.
